Yoda S, Lin JJ, Lawrence MS, et al. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound Mutations in ALK-Positive Lung Cancer. Cancer Discov. 2018;8(6):714-729. doi:10.1158/2159-8290.CD-17-1256
Kitajima S, Yoshida A, Kohno S, et al. The RB-IL-6 axis controls self-renewal and endocrine therapy resistance by fine-tuning mitochondrial activity. Oncogene. 2017;36(36):5145-5157. doi:10.1038/onc.2017.124
Sievers QL, Gasser JA, Cowley GS, Fischer ES, Ebert BL. Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4 activity. Blood. 2018;132(12):1293-1303. doi:10.1182/blood-2018-01-821769
Awad MM, Liu S, Rybkin II, et al. Acquired Resistance to KRAS Inhibition in Cancer. N Engl J Med. 2021;384(25):2382-2393. doi:10.1056/NEJMoa2105281
Viswanathan VS, Ryan MJ, Dhruv HD, et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017;547(7664):453-457. doi:10.1038/nature23007
Iniguez AB, Alexe G, Wang EJ, et al. Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling. Cancer Cell. 2018;34(6):922-938.e7. doi:10.1016/j.ccell.2018.11.005
Sandoval GJ, Hahn WC. Going beyond genetics to discover cancer targets. Genome Biol. 2017;18(1):95. doi:10.1186/s13059-017-1238-7
Hinze L, Pfirrmann M, Karim S, et al. Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias. Cancer Cell. 2019;35(4):664-676.e7. doi:10.1016/j.ccell.2019.03.004
Joung J, Engreitz JM, Konermann S, et al. Genome-scale activation screen identifies a lncRNA locus regulating a gene neighbourhood. Nature. 2017;548(7667):343-346. doi:10.1038/nature23451
Sade-Feldman M, Jiao YJ, Chen JH, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017;8(1):1136. doi:10.1038/s41467-017-01062-w